Recent articles
Here's Why Albemarle Rose as Much as 11.1% Today
The world's largest lithium producer announced full-year 2018 earnings and provided guidance for the year ahead.
Is Acceleron Pharma a Buy?
The $2 billion development-stage company is about to file for regulatory approval of its lead drug candidate.
Ecolab Expects Double-Digit Earnings Growth in 2019 (Sort of)
The $48 billion conglomerate maintained the preliminary guidance offered weeks ago, but it needs to improve operating margin.
FMC Corporation Expects Growth to Slow in the First Half of 2019
Rising raw materials costs will create a sluggish start to the year, but management thinks price increases will recoup those expenses before the end of 2019.
Here's Why These Gold Stocks Are Soaring Today
Gold prices hit a 10-month high as concerns spread over a global economic slowdown.
Green Plains Turns to a New Strategy in 2019: Curtailment
Will producing less help to balance the market? Only if peers follow suit.
3 Top Growth Stocks to Buy Right Now
Investors looking to inject growth into their portfolios should give these companies a closer look.
Here's Why Vanda Pharmaceuticals Gained as Much as 11.1% Today
The pharma company reported fourth-quarter and full-year 2018 operating results.
Here's Why CorMedix Dropped as Much as 27.1% Today
The company announced an update after meeting the FDA.
Here's Why Brookdale Senior Living Fell as Much as 17.2% Today
The nursing home operator's fourth-quarter losses and tepid outlook disappointed investors.
Here's Why Viking Therapeutics Rose as Much as 13.9% Today
A rival's setback is this small cap's gain, right?
Here's Why Tronox Gained as Much as 20.2% Today
The titanium dioxide manufacturer announced progress on its proposed acquisition of Cristal.
The 1 Stock I'd Buy Right Now
Most investors have probably never heard of this small-cap laboratory equipment supplier, but it reached an important inflection point in 2018.
Here's Why Coherus BioSciences Rose 48.7% in January
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
Here's Why Cara Therapeutics Stock Rose 17.3% in January
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
Here's Why CRISPR Therapeutics Rose 13.5% in January
The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.
Here's Why Flexion Therapeutics Rose 29.8% in January
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
Here's Why Lexicon Pharmaceuticals Lost 28.8% in January
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
2 Renewable Energy Stocks to Buy in February
Two well-managed renewable energy businesses are not getting much love from Wall Street right now, but the high-yield stocks are great long-term buys.
Here's Why Sage Therapeutics Gained 48.9% in January
The pharma company reported positive results from an important phase 3 trial.